Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Sandhoff disease is a severe neurodegenerative glycosphingolipid (GSL) lysosomal storage disorder, currently without treatment options. One therapeutic approach under investigation is substrate reduction therapy (SRT). By partially inhibiting GSL biosynthesis, the impaired rate of GSL catabolism is balanced by a slower rate of influx of GSLs into the lysosome. In a previous study, we reported the beneficial effects of treating Sandhoff disease mice with the glucose analogue N-butyldeoxynojirimycin (NB-DNJ), a compound that inhibits the first step of GSL biosynthesis catalysed by the ceramide specific glucosyltransferase. NB-DNJ, however, exhibits adverse effects at high doses such as weight loss and GI tract distress (due to glucosidase inhibition). This might limit the therapeutic potential of NB-DNJ for treating diseases affecting the CNS where high dose therapy may be required to achieve therapeutic levels of the drug in the brain. In the present study, a more selective compound, the galactose analogue N-butyldeoxygalactonojirimycin (NB-DGJ), was evaluated in the Sandhoff disease mouse model. Treatment with NB-DGJ showed greater therapeutic efficacy than NB-DNJ with no detectable side effects. The ability to escalate the dose of NB-DGJ, leading to extended life expectancy and increased delay in symptom onset, demonstrates the greater therapeutic potential of NB-DGJ for the treatment of the human gangliosidoses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sango, K., Yamanaka, S., Hoffmann, A., Okuda, Y., Grinberg, A., Westphal, H., McDonald, M. P., Crawley, J. N., Sandhoff, K., Suzuki, K., et al. (1995) · Nature Genetics · doi:10.1038/ng1095-170 · Cited by 468 · cited 1×
“Richard Proia (National Institute of Health, Bethesda, MD 20892; Sango et al., 1995).”
Background
Cited by
Pastores, G. M. (2012) · Swaiman's Pediatric Neurology · doi:10.1016/b978-1-4377-0435-8.00036-6 · Cited by 633
Sphingolipid metabolism diseases
Kolter, T., & Sandhoff, K. (2006) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.05.027 · Cited by 367
Vellodi, A. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05293.x · Cited by 295
Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease
Lee, J.-P., Jeyakumar, M., Gonzalez, R., Takahashi, H., Lee, P.-J., Baek, R. C., Clark, D., Rose, H., Fu, G., Clarke, J., et al. (2007) · Nature Medicine · doi:10.1038/nm1548 · Cited by 287
Self-citationGangliosides and Gangliosidoses: Principles of Molecular and Metabolic Pathogenesis
Sandhoff, K., & Harzer, K. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.0822-13.2013 · Cited by 280
Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics
Parenti, G. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900036 · Cited by 273
Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders
Coutinho, M., Santos, J., & Alves, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071065 · Cited by 116
Free oligosaccharide regulation during mammalian protein N-glycosylation
Chantret, I., & Moore, S. E. H. (2007) · Glycobiology · doi:10.1093/glycob/cwn003 · Cited by 75
Imino sugars are potent agonists of the human glucose sensor SGLT3
Voss, A. A., Díez-Sampedro, A., Hirayama, B. A., Loo, D. D. F., & Wright, E. M. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.030288 · Cited by 59
“Furthermore, in similar clinical trials (Andersson et al., 2004), adverse gastrointestinal effects of NB-DNJ are not observed with the galactose isomer N-butyl-1-deoxygalactonojirimycin.”
Background
Metadata
- Authors
- Andersson, U., Smith, D., Jeyakumar, M., Butters, T. D., Borja, M. C., Dwek, R. A., & Platt, F. M.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2004-08
- Volume
- 16
- Issue
- 3
- Pages
- 506-515
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2083102048
- Cited by
- 78
- References
- 1
- FWCI
- 4.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.